Irbesartan and amlodipine in the treatment of patients with microalbuminuria, hypertension and type 2 diabetes in Taiwan: a modelling projection over 25 years

References

• Yang WC, Hwang SJ, Chiang SS, et al. The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan. Diabetes Research and Clinical Practice 2001; 54((Suppl. 1))S47–S54
   Google Scholar
• Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases 1999; 34: 795–808
   PubMed Web of Science ®Google Scholar
• Wei JN, Sung FC, Lin CC, et al. National surveillance for type 2 diabetes mellitus in Taiwanese children. Journal of the American Medical Association 2003; 290: 1345–1350
   PubMed Web of Science ®Google Scholar
• Chou P, Li CL, Tsai ST. Epidemiology of type 2 diabetes in Taiwan. Diabetes Research and Clinical Practice 2001; 54((Suppl. 1))S29–S35
   Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2001; 345: 870–878
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001; 345: 861–869
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897–1903
   PubMed Web of Science ®Google Scholar
• Yang WC, Hwang SJ. Annual Data Report of Taiwan Renal Registry 2004
   Google Scholar
• Wu M, Lein J. Twenty Years Results of Kidney Transplantation at Taichung Veterans General Hospital 2000
   Google Scholar
• Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care 1998; 21: 1138–1145
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157–1165
   PubMed Web of Science ®Google Scholar
• Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 2001; 134: 629–636
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension 2001; 19: 1149–1159
   PubMed Web of Science ®Google Scholar
• Rodby RA, Rohde RD, Clarke WR, et al. The irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrology, Dialysis, Transplantation 2000; 15: 487–497
   PubMed Web of Science ®Google Scholar
• Tarn T, Smith M. Pharmacoeconomic Guidelines Around the World. ISPOR Connections 2004
   Google Scholar
• Souchet T, Durand Zaleski I, Hannedouche T, et al. RENAAL study. An economic evaluation of losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes & Metabolism 2003; 29: 29–35
   PubMed Web of Science ®Google Scholar
• Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland–an analysis of the RENAAL study. Swiss Medical Weekly 2004; 134: 440–447
   PubMed Web of Science ®Google Scholar
• Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26: 683–687
   PubMed Web of Science ®Google Scholar
• Burgess ED, Carides GW, Gerth WC, et al. Canadian Hypertension Society. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective. Canadian Journal of Cardiology 2004; 20: 613–618
   PubMed Web of Science ®Google Scholar
• Ravera M, Re M, Vettoretti S. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy. Journal of the American Society of Nephrology 2006; 17((4 Suppl. 2)):S44–S48
   Web of Science ®Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrology, Dialysis, Transplantation 2003; 18: 2059–2066
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension. Deutsche Medizinische Wochenschrift 2004; 129: 13–18, [in German]
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Borsos K, Annemans L, et al. Cost-effectiveness analysis of irbesartan in the treatment of type 2 diabetic patients complicated with hypertension and nephropathy. Hypertonia És Nephrologia 2004; 8
   Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. Grupo de Estudio Colaborativo IDNT. Cost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy. A Spanish perspective. Nefrologiá 2004; 24: 231–238, [in Spanish]
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of Human Hypertension 2004; 18: 733–738
   PubMed Web of Science ®Google Scholar
• Palmer A, Tucker D, Valentine WJ, et al. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrology, Dialysis, Transplantation 2005; 20: 1103–1109
   PubMed Web of Science ®Google Scholar